2026年保通战提前打响，股价下跌近半年的博安生物(06955)何以企稳反弹？

Core Viewpoint - The stock price of Bohan Biotech (06955) has experienced a significant decline since reaching a peak of HKD 19.90 on August 8 last year, with a low of HKD 8.15 on January 5 this year, marking a volatility of 59.05% [1]. Group 1: Stock Performance and Market Sentiment - Since August 8, Bohan Biotech has been in a downward trend characterized by "price drop and volume shrinkage," with the stock price fluctuating between the Bollinger Bands' middle and lower bands [2]. - The stock attempted a rebound after touching the lower Bollinger Band on August 20, but failed due to a lack of trading volume and market enthusiasm [2]. - A significant bullish candle on September 16 saw a 12% increase in stock price, but did not improve overall market sentiment, leading to continued downward pressure [4]. - The stock price showed signs of a potential rebound after touching the lower Bollinger Band for the sixth time on January 2, with a notable increase in trading volume on January 9 [5]. Group 2: Financial Performance and Market Position - Bohan Biotech's market capitalization was HKD 53.12 billion at the end of last year, but the current stock price is below HKD 60 billion, which is necessary to maintain its position in the Hong Kong Stock Connect [1]. - The company reported a revenue of HKD 393 million for the first half of 2025, a year-on-year increase of 8.39%, but net profit fell by 66.74% due to a high base from the previous year [7]. - Despite the decline in net profit, the company maintained a gross margin of 71.83% and a significant increase in cash flow, with cash and cash equivalents reaching HKD 660 million, up 231.86% year-on-year [7]. Group 3: Future Prospects and Pipeline - The upcoming review period for the Hong Kong Stock Connect is set for September 7, with the average market capitalization requirement being HKD 66.74 billion, only slightly below the current market cap of HKD 69.14 billion [6]. - Bohan Biotech has promising research pipelines, including a PD-1/IL-2 antibody fusion protein PR201, which is expected to submit an IND application in Q2 2026, and PR203, a dual-target antibody with potential for significant business development opportunities [8].